Recombinant staphylococcus thioredoxin reductase, and inhibitors thereof useful as antimicrobial agents

ABSTRACT

Isolated and purified Staphylococcus thioredoxin reductases (TrxB) are provided. Polynucleotides encoding the TrxBs, vectors and host cells containing such polynucleotides are also provided. In addition, antibodies reactive with the TrxBs are provided, as are methods of isolating the TrxBs, as well as methods for producing recombinant TrxBs, using TrxBs for screening compounds for TrxB-modulating activity, and detecting Staphylococcus in a test sample.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional of co-pending U.S. patent application Ser. No. 09/261,301 filed on Mar. 2, 1999, which claims the benefit of U.S. Provisional Patent Application Serial No. 60/076,525, filed on Mar. 2, 1998, the disclosure of each of which is incorporated herein by reference.

TECHNICAL FIELD

[0002] This invention relates generally to microbial metabolism and antimicrobial therapeutic agents. In particular, the invention relates to the bacterial enzyme thioredoxin reductase, to compounds that inhibit this enzyme, and to the use of these compounds as antimicrobial agents, particularly for the therapy of infections caused by Staphylococcus spp.

BACKGROUND OF THE INVENTION

[0003] The thioredoxin system is composed of NADPH, thioredoxin (Trx) and the flavoenzyme thioredoxin reductase (TrxB). Trx reduction by TrxB involves two half-reactions. In the first half-reaction, the FAD prosthetic group of TrxB is reduced by NADPH and electrons are transferred to cysteines present in the active site of TrxB. In the second half-reaction, oxidized Trx is reduced by TrxB. The thioredoxin system serves to transfer reducing equivalents for reductive enzymes such as ribonucleotide reductase, methionine sulfoxide reductase and vitamin K epoxide reductase. It also mediates protein folding and exerts specific redox control of some transcription factors to modulate their binding to DNA.

[0004] The thioredoxin system is of particular importance for redox metabolism in some Gram-positive bacteria. In this regard, certain Gram-positive bacteria, such as staphylococci, lack detectable glutathione (GSH) and glutathione reductase (GSR) which together play a key role in maintaining intracellular thiol-disulfide balance. GSH is the predominant thiol produced by aerobic eukaryotes and some Gram-positive bacteria, is believed to protect aerobic organisms from oxygen toxicity, and participates in a multitude of functions. For example, GSH plays a pivotal role in management of oxidative stress and maintenance and regulation of the redox balance. It acts as a cofactor for peroxide and ribonucleotide reductions, and serves in the conjugation and detoxification of foreign substances. Most organisms contain millimolar intracellular concentrations of GSH which, in concert with GSR and glutathione peroxidase, governs the redox status of the cellular environment. Thus, in microorganisms lacking the glutathione system, such as Staphylococcus aureus, the thioredoxin system, which is able to substitute for some of the glutathione-dependent processes, is of utmost importance.

[0005] The TrxB component of the thioredoxin system is a FAD-containing enzyme and belongs to a family of pyridine nucleotide-disulfide oxidoreductases. The bacterial enzyme obtained from Streptomyces clavuligerus, is a homodimer of 35 kDa subunits and has a native molecular weight of approximately 70 kDa. Aharonowitz et al. (1993) J. Bacteriol. 175:623-629. Each subunit of TrxB contains NADPH- and FAD- binding domains and includes an oxidoreductase active dithiol in the conserved sequence -CAT/VC-. Since the cysteine residues of TrxB are relatively inaccessible to the substrate thioredoxin, the enzyme appears to undergo a large conformational change during catalysis.

[0006] TrxBs from different mammalian species including calf (Holmgren, A. (1997) J. Biol. Chem. 252:4600-4606), rat (Luthman et al. (1982) Biochem. 21:66628-6633), and human (Arscott, et al. (1997) Proc. Natl. Acad. Sci. USA 94:3621-3626), have been purified and biochemically characterized. The rat liver TrxB has been isolated as a 116 kDa homodimer of 58 kDa subunits, and the mass of human placental TrxB estimated to be 160 kDa by gel-filtration chromatography and 130 kDa (two 65 kDa subunits) by sucrose density gradient centrifugation. The size difference between human TrxB and the smaller bacterial TrxBs is primarily due to differences in the dimer-interface domain. The redox-active cysteines of human TrxB are located in the FAD domain with a 4-amino acid bridge linking the two cysteines. The active-site disulfide of bacterial TrxBs, on the other hand, is located within the NADPH domain and a 2-amino acid bridge links the two cysteines. The 3D structure of the human TrxB is likely to be more similar to GSR than to the bacterial TrxB. Thus, primary amino acid sequence alignment of human TrxB with bacterial TrxB sequences reveals just 23-31% identity, whereas alignment of the human TrxB with GSRs of different sources shows 35-44% identity. Arscott, et al. (1997) Proc. Natl. Acad. Sci. USA 94:3621-3626.

[0007] Based on the significant differences that exist between the bacterial and the mammalian trxB genes, and the enzymes encoded thereby, the bacterial TrxB provides a potential target for the development of novel antibacterial drugs with a high degree of selectivity.

[0008] Antimicrobial agents commonly used to combat bacterial infections generally interfere with one or more critical steps in the metabolism of the bacterium, resulting in growth inhibition or death of the microbe. However, pathogenic microorganisms, including staphylococci, are developing resistance, and in many cases multiple resistances, to existing antimicrobial agents. In this regard, S. aureus is an opportunistic pathogen of increasing medical concern. It can be aggressively invasive, spreading rapidly through soft tissues, directly invading bones and even entering the bloodstream to produce septic shock and disseminated intravascular coagulation. Infections caused by staphylococci generally fall within one of two categories: those related to toxins produced by the bacterium exclusively, including gastroenteritis, toxic shock syndrome, scalded skin syndrome, and the like; and those related to direct invasion and systemic spread of the organism, including dermal infections, bone and joint infections, staphylococcal pneumonia and empyema, meningitis, cerebritis, endocarditis, bacteremia, septic shock, and the like.

[0009] These staphylococcal infections have traditionally been treated with β-lactam antibiotics. However, strains of β-lactam antibiotic-resistant staphylococci (BLARS), such as methicillin-resistant S. aureus (MRSA), have developed and become a widespread cause of fatal nosocomial infection. Infections caused by such resistant staphylococci are treated predominantly with “last resort” antibiotics such as vancomycin. Since resistance to these antibiotics would essentially exhaust the current therapeutic arsenal, it is essential that new antibacterial agents be identified.

SUMMARY OF THE INVENTION

[0010] The inventors herein have identified a bacterial thioredoxin reductase (TrxB) from Staphylococcus spp. that catalyzes, in two half-reactions, the specific NADPH-dependent reduction of thioredoxin (Trx), with the concomitant oxidation of NADPH to NADP⁺. In the first half-reaction, the FAD prosthetic group of TrxB is reduced by NADPH and electrons are transferred to cysteines present in the active site of TrxB. In the second half-reaction, oxidized Trx is reduced by TrxB.

[0011] The thioredoxin system provides a significant metabolic function in staphylococci and other Gram-positive bacteria that do not produce glutathione (GSH). The thioredoxin system catalyzes a broad range of protein thiol-disulfide exchange reactions, donates hydrogen for ribonucleotide reductase which is an essential enzyme in DNA synthesis, and is involved in redox regulation of numerous enzyme activities.

[0012] Staphylococcal TrxB differs significantly in its function from that of the mammalian enzyme in two important ways. First, it operates in an intracellular environment lacking GSH and GSH-dependent reductases. Second, its subunits are appreciably smaller than the mammalian enzyme and the dimeric enzyme possesses a substrate specificity distinct from its mammalian counterpart. Inhibition of Staphylococcal TrxB activity may cause depletion of reduced low molecular weight thiols, increase protein thiol oxidation, and interfere with DNA synthesis and radical scavenging. Such compromised cells are more likely to succumb to environmental challenges, such as those posed by the host immune system.

[0013] Consequently, bacterial TrxB provides an excellent target for the development of novel antibacterial drugs with a high degree of selectivity.

[0014] Such antibacterials act by inhibiting TrxB, thereby incapacitating the target bacterium, with few or no side-effects to the eukaryotic host organism. As a result, inhibitors of TrxB activity are effective antimicrobial agents against Staphylococcus and other microorganisms that depend on TrxB for their redox reactions.

[0015] The invention is directed to a method for identifying a compound that modulates Staphylococcus TrxB activity, comprising:

[0016] (a) providing a Staphylococcus TrxB polypeptide comprising an amino acid sequence having Staphylococcus thioredoxin reductase activity capable of catalyzing a specific reduction of thioredoxin with a concomitant oxidation of NADPH to NADP⁺;

[0017] (b) contacting a test compound with the TrxB polypeptide in the presence of thioredoxin, NADPH and a disulfide-containing substrate, under conditions that favor reduction of the disulfide-containing substrate;

[0018] (c) detecting the presence of free sulfhydryl groups formed by the reduction of disulfides of the disulfide-containing substrate, as a measure of TrxB activity,

[0019] thereby identifying a compound that modulates Staphylococcus TrxB activity.

[0020] The invention is further directed to compounds identified by these methods, compositions comprising the compounds and methods of treating Staphylococcus infections in an infected subject, comprising administering effective antibacterial amounts of the compositions.

[0021] These and other embodiments of the present invention will readily occur to those of ordinary skill in the art in view of the disclosure herein.

BRIEF DESCRIPTION OF THE FIGURES

[0022]FIG. 1 depicts the nucleotide sequence (SEQ ID NO:1) of the S. aureus trxB open reading frame.

[0023]FIG. 2 shows the deduced amino acid sequence (SEQ ID NO:2) of S. aureus TrxB derived from the nucleotide sequence of the open reading frame.

[0024]FIG. 3 is a diagram of vector pAUL-A.

[0025]FIG. 4 is a diagram of disruption vector pOI7.

[0026]FIGS. 5A and 5B show the method used to construct the gene replacement vector pOI5. FIG. 5A shows the construction of plasmid pOI4 used to construct plasmid pOI5, shown in FIG. 5B.

[0027]FIG. 6 depicts the nucleotide sequence (SEQ ID NO:9) of the S. epidermidis trxB open reading frame.

[0028]FIG. 7 shows an alignment of the TrxB enzymes from S. aureus (designated TrxB_(—) Sa, SEQ ID NO:2) and S. epidermidis (designated TrxB_(—) Se, SEQ ID NO:10). Colons indicate conservative amino acid substitutions and single dots indicate somewhat conservative substitutions.

[0029]FIG. 8 is a flow chart depicting a method for identifying TrxB inhibitors using an insulin turbidity test.

DETAILED DESCRIPTION

[0030] The practice of the present invention will employ, unless otherwise indicated, conventional techniques of molecular biology, microbiology and recombinant DNA technology, which are within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989); DNA Cloning, Vols. I and II (D. N. Glover ed. 1985); the series, Methods In Enzymology (S. Colowick and N. Kaplan eds., Academic Press, Inc.); Scopes, Protein Purification: Principles and Practice (2nd ed., Springer-Verlag); and PCR: A Practical Approach (McPherson et al. eds. (1991) IRL Press).

[0031] All patents, patent applications and publications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.

[0032] As used in this specification and the appended claims, the singular forms “a,” “an” and “the” include plural references unless the content clearly dictates otherwise.

A. Definitions

[0033] In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.

[0034] The term “polynucleotide” as used herein means a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. This term refers only to the primary structure of the molecule. Thus, the term includes double- and single-stranded DNA, as well as double- and single-stranded RNA. It also includes modifications, such as by methylation and/or by capping, and unmodified forms of the polynucleotide.

[0035] “Polypeptide” and “protein” are used interchangeably herein and indicate a molecular chain of amino acids linked through peptide bonds. The terms do not refer to a specific length of the product. Thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. The terms include post-translation modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations, and the like. In addition, protein fragments, analogs, muteins, fusion proteins and the like are included within the meaning of polypeptide.

[0036] Thus, by “TrxB polypeptide” is meant a polypeptide, whether isolated, recombinant or synthetic, comprising an amino acid sequence identical to that depicted in FIGS. 2 (SEQ ID NO:2) or 10 (SEQ ID NO:10), and fragments thereof that include as much of the molecule as necessary for the polypeptide to retain biological activity, e.g., catalytic and/or immunological activity, as well as analogs, mutated or variant proteins, and the like, thereof that retain such activity. Generally, if catalytic activity is required, the polypeptide will include the NADPH- and FAD-binding domains, as well as a redox active site. The NADPH domain is found at residues 146-161 of FIGS. 2 and 10. Two FAD domains are present, and found at residues 6-21 and 267-277, of FIGS. 2 and 10. Finally, the redox active site is found at residues 134-137 and includes the amino acid sequence CAVC. Thus, if catalytic activity is desired, the polypeptide can include about amino acid residues 1-277 or more of FIGS. 2 or 10, or will include the above specified portions, with internal regions deleted, so long as catalytic activity is retained. If immunological activity is desired, e.g., the ability to raise antibodies for use in assays, immunopurification, and the like, the protein will contain one or more epitopes capable of eliciting a humoral antibody response. Normally, an epitope will include between about 3-20 amino acids, generally about 8-10, and preferably about 15-20 or more amino acids, derived from the TrxB molecule.

[0037] By sequence “similarity” between two amino acid sequences is meant an exact amino acid to amino acid comparison of two or more polypeptides at appropriate portions of the molecule, where identical amino acids are aligned, and where residues are not identical, aligned based on similar chemical and/or physical properties such as charge or hydrophobicity. “Percent similarity” can be determined between the compared polypeptide sequences using techniques well known in the art.

[0038] In general, “identity” refers to an exact nucleotide to nucleotide or amino acid to amino acid correspondence of two or more polynucleotide or polypeptide sequences, respectively. Techniques for determining nucleic acid and amino acid “sequence identity” are well known in the art and include determining the nucleotide sequence of the MRNA for the gene of interest (usually via a cDNA intermediate) and determining the amino acid sequence encoded thereby, and comparing this to a second amino acid sequence. Programs available in the Wisconsin Sequence Analysis Package, Version 8 (available from Genetics Computer Group, Madison, Wis.) for example, the GAP program, are capable of calculating both the identity between two polynucleotides and the identity and similarity between two polypeptide sequences. Other programs for calculating identity or similarity between sequences are known in the art.

[0039] Generally, a polypeptide analog of TrxB will have at least about 50% identity, preferably about 60% identity, more preferably about 75-85% identity, and most preferably about 90-95% or more identity, to the reference TrxB sequence. Further, the polypeptide may have at least about 60% similarity, preferably at least about 75% similarity, more preferably about 85% similarity, and most preferably about 95% or more similarity to the reference sequence. Additionally, a polynucleotide variant will display at least about 50% identity, preferably about 60% identity, more preferably about 75-85% identity, and most preferably about 90-95% or more identity, to the reference trxB nucleotide sequence.

[0040] By the term “degenerate variant” or “structurally conserved mutation” is intended a polynucleotide containing changes in the nucleic acid sequence thereof, such as insertions, deletions or substitutions, that encodes a polypeptide having the same amino acid sequence as the polypeptide encoded by the polynucleotide from which the degenerate variant is derived. “Recombinant host cells,” “host cells,” “cells,” “cell lines,” “cell cultures,” and other such terms denoting microorganisms or higher eukaryotic cell lines cultured as unicellular entities refer to cells which can be, or have been, used as recipients for recombinant vectors or other transfer DNA, immaterial of the method by which the DNA is introduced into the cell or the subsequent disposition of the cell. The terms include the progeny of the original cell which has been transfected.

[0041] A “vector” is a replicon in which another polynucleotide segment is attached, such as to bring about the replication and/or expression of the attached segment. The term includes expression vectors, cloning vectors, and the like.

[0042] The term “control sequence” refers to a polynucleotide sequence which effects the expression of coding sequences to which it is ligated. The nature of such a control sequence differs depending upon the host organism. In prokaryotes, such control sequences generally include a promoter, a ribosomal binding site, and a terminator. In eukaryotes, such control sequences generally include a promoter, a terminator and, in some instances, an enhancer. The term “control sequence” thus is intended to include at a minimum all components necessary for expression, and also may include additional components whose presence is advantageous, for example, leader sequences.

[0043] A “coding sequence” is a polynucleotide sequence that is transcribed into mRNA and/or translated into a polypeptide when placed under the control of appropriate regulatory sequences. The boundaries of the coding sequence are determined by a translation start codon at the 5′-terminus and a translation stop codon at the 3′-terminus. A coding sequence can include, but is not limited to, mRNA, cDNA, and recombinant polynucleotide sequences. Mutants or analogs may be prepared by the deletion of a portion of the coding sequence, by insertion of a sequence, and/or by substitution of one or more nucleotides within the sequence. Techniques for modifying nucleotide sequences, such as site-directed mutagenesis, are well known to those skilled in the art. See, e.g., Sambrook et al., supra; DNA Cloning, Vols. I and II, supra; Nucleic Acid Hybridization, supra.

[0044] “Operably linked” refers to a situation wherein the components described are in a relationship permitting them to function in their intended manner. Thus, for example, a control sequence “operably linked” to a coding sequence is ligated in such a manner that expression of the coding sequence is achieved under conditions compatible with the control sequences. A coding sequence may be operably linked to control sequences that direct the transcription of the polynucleotide whereby said polynucleotide is expressed in a host cell. “Transformation” refers to the insertion of an exogenous polynucleotide into a host cell, irrespective of the method used for the insertion, or the molecular form of the polynucleotide that is inserted. For example, injection, direct uptake, transduction, and f-mating are included. Furthermore, the insertion of a polynucleotide per se and the insertion of a plasmid or vector comprised of the exogenous polynucleotide, are also included. The exogenous polynucleotide may be directly transcribed and translated by the cell, maintained as a nonintegrated vector, for example, a plasmid, or alternatively, may be stably integrated into the host genome.

[0045] The term “probe” denotes a defined nucleic acid segment which can be used to identify a specific polynucleotide present in samples bearing the complementary sequence. A probe will generally include about 8 to about 75 contiguous nucleic acids of the reference polynucleotide, generally about 12 to about 50 contiguous nucleic acids, and preferably about 15-18 to about 30 contiguous nucleic acids of the reference sequence.

[0046] The term “isolated,” when referring to a polynucleotide or a polypeptide, intends that the indicated molecule is present in the substantial absence of other similar biological macro-molecules of the same type. The term “isolated” as used herein means that at least 75 wt. %, more preferably at least 85 wt. %, more preferably still at least 95 wt. %, and most preferably at least 98 wt. % of a composition is the isolated polynucleotide or polypeptide. An “isolated polynucleotide” that encodes a particular polypeptide refers to a polynucleotide that is substantially free of other nucleic acid molecules that do not encode the subject polypeptide; however, the molecule may include conservative mutations as defined herein. Thus, an isolated polynucleotide would not be a polynucleotide as it exists on the chromosome.

[0047] The term “test sample” refers to a component of an individual's body which is the source of an analyte, such as antibodies or antigens of interest. These test samples include biological samples which can be tested by the methods of the present invention described herein and include human and animal body fluids such as whole blood, serum, plasma, cerebrospinal fluid, urine, lymph fluids, and various external secretions of the respiratory, intestinal and genitorurinary tracts, tears, saliva, milk, white blood cells, myelomas and the like; biological fluids such as cell culture supernatants; fixed tissue specimens; and fixed cell specimens.

[0048] The following single-letter amino acid abbreviations are used throughout the text: Alanine A Arginine R Asparagine N Aspartic acid D Cysteine C Glutamine Q Glutamic acid E Glycine G Histidine H Isoleucine I Leucine L Lysine K Methionine M Phenylalanine F Proline P Serine S Threonine T Tryptophan W Tyrosine Y Valine V

B. General Methods

[0049] The present invention is based on the identification of novel Staphylococcal TrxB polypeptides, including S. aureus TrxB (also termed TrxB_(—) Sa herein) and S. epidermidis TrxB (also termed TrxB_(—) Se herein), as well as polynucleotides encoding the TrxBs, and methods of making the TrxBs. The invention includes not only the enzyme but also methods for screening compounds for pharmacological activity using the enzyme, cells expressing the enzyme, antibodies to the enzyme and the use of polynucleotides and antibodies to diagnose the presence of Staphylococcus in a test sample.

[0050] In particular, the inventors herein have identified new TrxB enzymes in S. aureus and S. epidermidis. The native enzyme has a molecular mass (M_(r)) of approximately 70 kDa, as determined by gel filtration chromatography. The enzyme exists as a homodimer having a subunit M_(r) of about 35 kDa, as determined by SDS polyacrylamide gel electrophoresis. The predicted value of the Staphylococcal TrxB subunit molecular mass, based on the primary amino acid sequence is 33.518, and the calculated isoelectric point (PI) is 5.39. The gene encoding the S. aureus TrxB enzyme has been cloned and the ORF coding for the TrxB protein is shown in FIG. 1. The gene encodes a putative amino acid sequence of 311 amino acids, shown in FIG. 2.

[0051] Similarly, the gene encoding the S. epidermidis TrxB enzyme has been identified and the nucleotide and amino acid sequences are shown in FIGS. 6 and 7, respectively.

[0052] The enzyme can be isolated directly from bacteria as follows. Bacteria are cultured in a suitable culture medium, such as trypticase soy broth (TSB). The bacteria are then removed from the culture medium using standard techniques known in the art, such as by centrifugation or microfiltration or a combination of the two. For example, microfiltration using an appropriate filter will suffice to remove unwanted cellular debris.

[0053] Bacteria thus obtained are prepared to release the contents of the cytoplasm. Bacterial cells may be broken using methods and/or reagents known in the art that do not adversely affect the structure and/or the activity of the TrxB, e.g., exposure to freeze-thaw cycles, exposure to an ultrasonic disintegrator, homogenization, bead milling, chemical or enzymatic cell lysis, and the like. In one preferred method, cells are incubated in a buffer containing lysostaphin, a lytic agent for S. aureus, and then centrifuged to remove insoluble cellular debris.

[0054] The bacterial cell extract thus prepared can be further processed to separate the protein from the cellular debris, and provide an initial stage of purification and volume reduction. For example, the extract obtained from the previous step may be processed by a primary separation procedure such as ultrafiltration, i.e., passage through a filter having an appropriate molecular weight cut-off, to concentrate the sample by reducing the water and salt content. Alternatively, the extract may be precipitated by neutral salts such as ammonium sulphate, organic solvents such as ethanol, or other agents for recovering and purifying the protein. Preferably, Staphylococcus TrxB is precipitated from the extract by adding ammonium sulfate to the extract to approximately 30% to 50% saturation, preferably 40% saturation. The supernatant of the same is collected by, e.g., centrifugation, and the ammonium sulfate is adjusted to about 70% to 90%, preferably 80% saturation. The treated precipitate thus obtained is collected and used in further purification steps.

[0055] A number of protein purification operations may be used to further purify the Staphylococcus TrxB including adsorption chromatography, ion-exchange chromatography, hydrophobic interaction chromatography, affinity chromatography, chromatofocussing, gel-filtration, reversed-phase liquid chromatography, phosphocellulose chromatography, hydroxyapatite chromatography or lectin chromatography, any combination of such techniques. Protein refolding steps can be used, as necessary, in completing configuration of the protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.

[0056] For example, the fraction precipitating between 40-80% ammonium sulfate saturation can be applied to a gel-filtration matrix for size separation. Useful matrices for size separation include any of several known in the art such as, without limitation, those made of dextran, dextran/bisacrylamide, polyacrylamide, agarose, cross-linked agarose, agarose/polyacrylamide, and cross-linked polyethers. Particularly preferred matrices are those which allow fractionation of molecules in the size range of about 10⁴ to 10⁶, such as Sephacryl S-300, Sepharose 6B, Sepharose CL-6B, Ultragel AcA44, Ultragel AcA34, Ultragel A6, and the like.

[0057] Fractions from the size-separation step which exhibit TrxB and Trx activity can be pooled and applied to an ion-exchange column and proteins eluted with a linear salt gradient. Preferred ion-exchangers are anion-exchangers, well known in the art. Particularly preferred herein are relatively weak anion-exchangers, such as those including aminoethyl (AE) or diethylaminoethyl (DEAE) functionalities. Useful matrix materials include but are not limited to, cellulose matrices, such as fibrous, microgranular and beaded matrices; agarose, dextran, polyacrylate, polyvinyl, polystyrene, silica and polyether matrices; and composites. A representative anion-exchanger for use herein is DEAE-Sepharose.

[0058] TrxB activity can be monitored during purification using standard TrxB assays. For example, the presence of TrxB can be assayed spectrophotometrically by monitoring the NADPH- and TrxB disulfide-dependent reduction of a disulfide-containing substrate. One assay method monitors the reduction of 5,5′-dithio-bis-2-nitrobenzoic acid (DTNB) at 412 nm. See, e.g., Ellman (1959) Arch. Biochem. Biophys. 82:70-77. A particularly preferred assay uses insulin as the disulfide-containing substrate. The presence of free sulfhydryl (SH) groups in insulin are measured at 650 nm as an indication of TrxB activity. See, e.g., A. Holmgren and M. Bjomstedt, (1995) Methods in Enzymology 252:199-208; and the examples herein. In this reaction, TrxB specifically reduces thioredoxin (T-S₂) to T-(SH)₂ using NADPH. The formed T-(SH)₂ in turn reduces native insulin. Insulin can be replaced by any of several low molecular weight disulfide compounds in the assay, such as cystine, and TrxB activity is monitored spectrophotometrically following the oxidation of NADPH.

[0059] Following isolation, purity of fractions showing TrxB activity can be determined using any of several methods such as by SDS-PAGE.

[0060] Once purified, the amino acid sequences of the proteins can be determined, e.g., by repetitive cycles of Edman degradation, followed by amino acid analysis by HPLC. Other methods of amino acid sequencing are also known in the art. Based on knowledge of the amino acid sequence, DNA encoding the enzyme can be derived from genomic or cDNA, prepared by synthesis, or by a combination of techniques. The DNA can then be used to express the TrxB, or as a template for the preparation of RNA, using methods well known in the art (see, Sambrook et al., supra).

[0061] More particularly, DNA encoding the Staphylococcus TrxB may be obtained from an appropriate DNA library, e.g., an S. aureus or S. epidermidis genomic DNA library. DNA libraries may be probed using the procedure described by Grunstein et al. (1975) Proc. Natl. Acad. Sci. USA 73:3961. Briefly, the DNA to be probed is immobilized on nitrocellulose filters, denatured and prehybridized with a buffer which contains 0-50% formamide, 0.75 M NaCl, 75 mM Na citrate, 0.02% (w/v) each of bovine serum albumin (BSA), polyvinyl pyrollidone and Ficoll®, 50 mM Na phosphate (pH 6.5), 0.1% sodium dodecyl sulfate (SDS) and 100 μg/ml carrier denatured DNA. The percentage of formamide in the buffer, as well as the time and temperature conditions of the prehybridization and subsequent hybridization steps, depends on the stringency required. Oligomeric probes which require lower stringency conditions are generally used with low percentages of formamide, lower temperatures, and longer hybridization times. Probes containing more than 30 or 40 nucleotides such as those derived from cDNA or genomic sequences generally employ higher temperatures, for example, about 40° C. to 42° C., and a high percentage, for example, 50%, formamide. Following prehybridization, a ³²P-labelled oligonucleotide probe is added to the buffer, and the filters are incubated in this mixture under hybridization conditions. After washing, the treated filters are subjected to autoradiography to show the location of the hybridized probe. DNA in corresponding locations on the original agar plates is used as the source of the desired DNA.

[0062] Synthetic oligonucleotides may be prepared using an automated oligonucleotide synthesizer such as that described by Warner (1984) DNA 3:401. If desired, the synthetic strands may be labeled with ³²P by treatment with polynucleotide kinase in the presence of ³²P-ATP, using standard conditions for the reaction. DNA sequences including those isolated from genomic or cDNA libraries, may be modified by known methods which include site-directed mutagenesis as described by Zoller (1982) Nucleic Acids Res. 10:6487. Briefly, the DNA to be modified is packaged into phage as a single stranded sequence, and converted to a double stranded DNA with DNA polymerase using, as a primer, a synthetic oligonucleotide complementary to the portion of the DNA to be modified, and having the desired modification included in its own sequence. Cultures of the transformed bacteria, which contain replications of each strand of the phage, are plated in agar to obtain plaques. Theoretically, 50% of the new plaques contain phage having the mutated sequence, and the remaining 50% have the original sequence. Replicates of the plaques are hybridized to labeled synthetic probe at temperatures and conditions suitable for hybridization with the correct strand, but not with the unmodified sequence. The sequences which have been identified by hybridization are recovered and cloned.

[0063] Once produced, the DNA may then be incorporated into a cloning or expression vector for replication in a suitable host cell. Vector construction employs methods known in the art. Generally, site-specific DNA cleavage is performed by treating with suitable restriction enzymes under conditions which generally are specified by the manufacturer of these commercially available enzymes. Usually, about 1 microgram (μg) of plasmid or DNA sequence is cleaved by 1-10 units of enzyme in about 20 μl of buffer solution by incubation at 37° C. for 1 to 2 hours. After incubation with the restriction enzyme, protein is removed by phenol/chloroform extraction and the DNA recovered by precipitation with ethanol. The cleaved fragments may be separated using polyacrylamide or agarose gel electrophoresis methods, according to methods known by those of skill in the art.

[0064] Sticky end cleavage fragments may be blunt ended using E. coli DNA polymerase 1 (Klenow) in the presence of the appropriate deoxynucleotide triphosphates (dNTPs) present in the mixture. Treatment with S1 nuclease also may be used, resulting in the hydrolysis of any single stranded DNA portions.

[0065] Ligations are performed using standard buffer and temperature conditions using T4 DNA ligase and ATP. Sticky-end ligations require less ATP and less ligase than blunt-end ligations. When vector fragments are used as part of a ligation mixture, the vector fragment often is treated with bacterial alkaline phosphatase (BAP) or calf intestinal alkaline phosphatase to remove the 5′-phosphate and thus prevent religation of the vector. Alternatively, restriction enzyme digestion of unwanted fragments can be used to prevent ligation.

[0066] For standard vector constructions, ligation mixtures are transformed into a suitable host, and successful transformants selected by antibiotic resistance or other markers. Plasmids from the transformants can then be prepared according to the method of Clewell et al. (1969) Proc. Natl. Acad. Sci. USA 62:1159 usually following chloramphenicol amplification as reported by Clewell et al. (1972) J. Bacteriol. 110:667. The DNA is isolated and analyzed usually by restriction enzyme analysis and/or sequencing. Sequencing may be by the well-known dideoxy method of Sanger et al. (1977) Proc. Natl. Acad. Sci. USA 74:5463) as further described by Messing et al. (1981) Nucleic Acid Res. 9:309, or by the method reported by Maxam et al. (1980) Meth. Enzymol. 65:499. Problems with band compression, which are sometimes observed in GC rich regions, are overcome by use of T-deazoguanosine according to the method reported by Barr et al. (1986) Biotechniques 4:428.

[0067] Host cells are genetically engineered (transduced, transformed, or transfected) with the vectors of this invention which may be a cloning vector or an expression vector. The vector may be in the form of a plasmid, a viral particle, a phage, etc. The engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the TrxB-encoding polynucleotide. The culture conditions, such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to those of skill in the art.

[0068] Both prokaryotic and eukaryotic host cells may be used for expression of desired coding sequences when appropriate control sequences that are compatible with the designated host are used. Among prokaryotic hosts, E. coli is frequently used. Expression control sequences for prokaryotes include promoters, optionally containing operator portions, and ribosome binding sites. Transfer vectors compatible with prokaryotic hosts are commonly derived from the plasmid pBR322 that contains operons conferring ampicillin and tetracycline resistance, and the various pUC vectors, that also contain sequences conferring antibiotic resistance markers. These markers may be used to obtain successful transformants by selection. Commonly used prokaryotic control sequences include the β-lactamase (penicillinase), lactose promoter system (Chang et al. (1977) Nature 198:1056), the tryptophan promoter system (reported by Goeddel et al. (1980) Nucleic Acid Res. 8:4057) and the lambda-derived P1 promoter and N gene ribosome binding site (Shimatake et al. (1981) Nature 292:128) and the hybrid Tac promoter (De Boer et al. (1983) Proc. Natl. Acad. Sci. USA 292:128) derived from sequences of the trp and lac UV5 promoters. The foregoing systems are particularly compatible with E. coli; however, other prokaryotic hosts such as strains of Bacillus or Pseudomonas may be used if desired, with corresponding control sequences.

[0069] Eukaryotic hosts include yeast and mammalian cells in culture systems. Saccharomyces cerevisiae and S. carlsbergensis are commonly used yeast hosts, and are convenient fungal hosts. Yeast-compatible vectors carry markers that permit selection of successful transformants by conferring protrophy to auxotrophic mutants or resistance to heavy metals on wild-type strains. Yeast compatible vectors may employ the 2-micron origin of replication (Broach et al. (1983) Meth. Enzymol. 101:307), the combination of CEN3 and ARS 1 or other means for assuring replication, such as sequences that will result in incorporation of an appropriate fragment into the host cell genome. Control sequences for yeast vectors are known in the art and include promoters for the synthesis of glycolytic enzymes, including the promoter for 3-phosphoglycerate kinase. See, for example, Hess et al. (1968) J. Adv. Enzyme Reg. 7:149, Holland et al. (1978) Biochemistry 17:4900, and Hitzeman (1980) J. Biol. Chem. 255:2073. Terminators also may be included, such as those derived from the enolase gene as reported by Holland (1981) J. Biol. Chem. 256:1385. It is contemplated that particularly useful control systems are those that comprise the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) promoter or alcohol dehydrogenase (ADH) regulatable promoter, terminators also derived from GAPDH, and, if secretion is desired, leader sequences from yeast alpha factor. In addition, the transcriptional regulatory region and the transcriptional initiation region which are operably linked may be such that they are not naturally associated in the wild-type organism.

[0070] Mammalian cell lines available as hosts for expression are known in the art and include many immortalized cell lines which are available from the American Type Culture Collection. These include HeLa cells, Chinese hamster ovary (CHO) cells, baby hamster kidney (BHK) cells, and others. Suitable promoters for mammalian cells also are known in the art and include viral promoters such as that from Simian Virus 40 (SV40), Rous sarcoma virus (RSV), adenovirus (ADV), bovine papilloma virus (BPV), cytomegalovirus (CMV). Mammalian cells also may require terminator sequences and poly A addition sequences; enhancer sequences which increase expression also may be included, and sequences which cause amplification of the gene also may be desirable. These sequences are known in the art. Vectors suitable for replication in mammalian cells may include viral replicons, or sequences which insure integration of the appropriate sequences encoding the Staphylococcus TrxB into the host genome.

[0071] Other eukaryotic systems are also known, as are methods for introducing polynucleotides into such systems, such as into amphibian cells, using known methods, and insect cells using methods described in Summers and Smith (1987), Texas Agricultural Experiment Station Bulletin No. 1555, and the like.

[0072] Transformation may be by any known method for introducing polynucleotides into a host cell, including packaging the polynucleotide in a virus and transducing a host cell with the virus, by direct uptake of the polynucleotide by the host cell, and the like. The transformation procedures selected depend upon the host to be transformed. Bacterial transformation by direct uptake generally employs treatment with calcium or rubidium chloride. Cohen (1972) Proc. Natl. Acad. Sci. USA 69:2110. Yeast transformation by direct uptake may be conducted using the calcium phosphate precipitation method of Graham et al. (1978) Virology 52:526, or modification thereof.

[0073] Expression of active TrxB can be assayed spectrophotometrically, as described above, by monitoring the NADPH- and TrxB disulfide-dependent reduction of a disulfide-containing substrate. Particularly useful substrates include DTNB and insulin. See, e.g., Ellman (1959) Arch. Biochem. Biophys. 82:70-77; and A. Holmgren and M. Bjornstedt, (1995) Methods in Enzymology 252:199-208. Alternatively, expression of TrxB can be monitored using an ELISA assay and antibodies prepared to the isolated TrxB enzyme. The enzyme is recovered and purified from recombinant host cell cultures expressing the same by known methods as described above.

[0074] The Staphylococcus TrxB polypeptide or fragments thereof, may also be synthesized by conventional techniques known in the art, for example, by chemical synthesis such as solid-phase peptide synthesis. In general, these methods employ either solid- or solution-phase synthesis methods, well known in the art. See, e.g., J. M. Stewart and J. D. Young, Solid Phase Peptide Synthesis, 2nd Ed., Pierce Chemical Co., Rockford, Ill. (1984) and G. Barany and R. B. Merrifield, The Peptides: Analysis, Synthesis, Biology, editors E. Gross and J. Meienhofer, Vol. 2, Academic Press, New York, (1980), pp. 3-254, for solid phase peptide synthesis techniques; and M. Bodansky, Principles of Peptide Synthesis, Springer-Verlag, Berlin (1984) and E. Gross and J. Meienhofer, Eds., The Peptides: Analysis, Synthesis, Biology, supra, Vol. 1, for classical solution synthesis.

[0075] Once obtained, the enzyme may be used to identify compounds that modulate Staphylococcus TrxB activity. Thus, as described above, enzyme activity and the effects of compounds on enzyme activity can be assayed spectrophotometrically by monitoring the NADPH- and TrxB disulfide-dependent reduction of 5,5′-dithio-bis-2-nitrobenzoic acid (DTNB) at 412 nm, or by measuring the presence of free SH groups of insulin at 650 nm. Purification or expression of Staphylococcus TrxB, and screening for compounds that inhibit the enzyme activity, provides a method for rapid selection of compounds with enzyme-inhibiting activity.

[0076] Compounds that inhibit Staphylococcus TrxB are considered potential therapeutic agents for use in treating several disorders caused by staphylococcal bacteria, including without limitation those caused by S. aureus, S. epidermidis, S. albus, S. hyicus, S. hyos, S. intermedius, S. simulans, and the like. These bacteria cause infection in man and other nonhuman primates, as well as in domestic animals, such as dogs and cats, and in farm animals, including horses, pigs, sheep, goats and cows. These agents are therefore useful in preventing or retarding growth and/or reproduction of the infecting microorganism in a wide variety of vertebrate subjects.

[0077] Examples of diseases for which TrxB inhibitors are useful therapeutic agents include any of the several infections caused by staphylococci including, but not limited to, gastroenteritis, enterocolitis, toxic shock syndrome, scalded skin syndrome, dermal infections, cellulitis, toxic epidermal necrolysis, ecthyma, necrotizing fasciitis, folliculitis, furuncles, carbuncles, impetigo, bone and joint infections, osteomyelitis, pneumonia and empyema, meningitis, cerebritis, endocarditis, bacteremia, septic shock, septicemia, food poisoning, enteritis, and the like.

[0078] The inhibitory compounds of the present invention can be formulated into pharmaceutical compositions in a variety of dosage forms such as, but not limited to, liquid solutions or suspensions, tablets, pills, powders, ointments suppositories, polymeric microcapsules or microvesicles, liposomes, and injectable or infusible solutions. The preferred form depends upon the mode of administration and the particular microorganism and disease targeted. The compositions also preferably include pharmaceutically acceptable vehicles, carriers or adjuvants, well known in the art, such as human serum albumin, ion exchangers, alumina, lecithin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, and salts or electrolytes such as protamine sulfate. Suitable vehicles are, for example, water, saline, dextrose, glycerol, ethanol, or the like, and combinations thereof. Actual methods of preparing such compositions are known, or will be apparent, to those skilled in the art. See, e.g., Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 18th edition, 1990.

[0079] The above compositions can be administered using conventional modes of delivery including, but not limited to, intramuscular, intravenous, intraperitoneal, oral, intralymphatic, or subcutaneous administration. Local administration to a tissue in question, or to a site of infection, e.g., direct injection into an infected joint, will also find use with the present invention.

[0080] Therapeutically effective doses will be easily determined by one of skill in the art and will depend on the severity and course of the disease, the patient's health and response to treatment, and the judgment of the treating physician.

[0081] Furthermore, the Staphylococcus TrxB polypeptide can be used to prepare polyclonal or monoclonal antibodies using techniques that are well known in the art. If polyclonal antibodies are desired, a selected mammal, (e.g., mouse, rabbit, goat, horse, etc.) is immunized with a TrxB polypeptide and serum from the immunized animal is collected and treated according to known procedures. See, e.g., Jurgens et al. (1985) J. Chrom. 348:363-370. If serum containing polyclonal antibodies is used, the polyclonal antibodies can be purified by immunoaffinity chromatography, using known procedures.

[0082] Monoclonal antibodies to the TrxB polypeptides can also be readily produced by one skilled in the art. The general methodology for making monoclonal antibodies using hybridoma technology is well known. Immortal antibody-producing cell lines can be created by cell fusion, as well as by other techniques, such as direct transformation of B-lymphocytes with oncogenic DNA, or transfection with Epstein-Barr virus. See, e.g., M. Schreier et al., Hybridoma Techniques (1980); Hammerling et al., Monoclonal Antibodies and T-cell Hybridomas (1981); Kennett et al., Monoclonal Antibodies (1980); U.S. Pat. Nos. 4,341,761; 4,399,121; 4,427,783; 4,444,887; 4,452,570; 4,466,917; 4,472,500, 4,491,632; and 4,493,890. Panels of monoclonal antibodies produced against the TrxB polypeptides can be screened for various properties; e.g., for isotype, epitope, affinity, etc. Monoclonal antibodies are useful in purification, using immunoaffinity techniques, of the TrxB polypeptides. Monoclonal and polyclonal antibodies that display specificity and selectivity for the enzyme can be labeled with a detectable moiety, e.g., a fluorescent moiety, and used in in vitro, or in situ immunofluorescent assays, or the like. The antibodies can be used to identify Staphylococcus for immunodiagnostic purposes.

[0083] In addition, DNA encoding the Staphylococcus TrxBs, or RNA derived therefrom, can be used to design oligonucleotide probes for Staphylococcus present in a host organism. As used herein, the term “probe” refers to a structure comprised of a polynucleotide, as defined above, which contains a nucleic acid sequence complementary to a nucleic acid sequence present in a target polynucleotide. The polynucleotide regions of probes may be composed of DNA, and/or RNA, and/or synthetic nucleotide analogs such as morpholino compounds and peptide nucleic acid (“PNA”) analogs. Such probes may be used in in vitro or in situ hybridization assays, or the like, and are useful, for example, for the diagnosis of microbial infections.

[0084] Using a determined portion of the isolated TrxB-encoding polynucleotide, oligomers of approximately eight or more nucleotides can be prepared, either by excision or synthetically, which hybridize with the TrxB-encoding polynucleotide. Such oligomers are useful, for example, for detecting the presence of bacteria in diseased individuals. The natural or derived probes for trxB polynucleotides are a length that allows the detection of unique sequences by hybridization. While 6-8 nucleotides may be a workable length, sequences of 10-12 nucleotides are preferred, and those of about 18-20 nucleotides, or more, most preferred. These probes can be prepared using routine, standard methods including automated oligonucleotide synthetic methods.

[0085] When the oligonucleotide probes are to be used as diagnostic reagents, the test sample to be analyzed, such as blood or serum, may be treated such as to extract a nucleic acid fraction thereof. The resulting nucleic acid from the sample may be subjected to gel electrophoresis or other size separation techniques, or the nucleic acid sample may be dot-blotted without size separation. The sample is then exposed to an oligonucleotide probe that has been detectably labeled. Suitable labels and methods for attaching labels to probes are known in the art, and include but are not limited to radioactive labels incorporated by nick translation or kinasing, biotin, fluorescent and chemiluminescent probes, enzymes which catalyze the production of a detectable product such as horseradish peroxidase, alkaline phosphatase, β-galactosidase, and the like. The nucleic acids extracted from the sample are then treated with the labeled probe under conditions of suitable hybridization stringency.

[0086] The stringency of hybridization is determined by a number of factors during the washing procedure, including temperature, ionic strength, length of time and concentration of formamide. Sambrook et al., supra. Hybridization can be carried out by a number of techniques. Amplification of the sample nucleic acid, if required, can be performed, for example, by ligase chain reaction (LCR), polymerase chain reaction (PCR), Q-beta replicase, NASBA, or other techniques well known in the art. The amplified nucleic acids then may be detected using a hybridization assay such as those known in the art.

[0087] TrxB, antibodies thereto, as well as polynucleotides encoding TrxB or portions thereof, can be provided in diagnostic kits. For example, oligomer probes capable of specifically hybridizing to a polynucleotide encoding a TrxB can be packaged in diagnostic kits which include the probe nucleic acid sequence which may be labelled. Alternatively, the probe may be provided, unlabelled and the ingredients for labelling can be included with the kit. The kit also may contain other suitably packaged reagents and materials needed or desirable for the particular hybridization protocol, for example, standards as well as instructions for performing the assay.

[0088] In addition, kits can include reagents for detecting of the presence and/or amount of Staphylococcus TrxB in a test sample, as well as for detecting the presence of Staphylococcus. Such reagents can comprise, e.g., an antibody capable of specifically binding to the TrxB polypeptide.

[0089] Furthermore, kits containing a Staphylococcus TrxB polypeptide in a suitable container are provided for screening compounds for TrxB-modulating activity or for screening test samples for the presence of a TrxB antibody. It is contemplated that reagents employed in the above kits can be provided in one or more containers such as vials or bottles, with each container containing a separate reagent such as a monoclonal antibody, or a cocktail of monoclonal antibodies, or a polypeptide (either recombinant or synthetic) employed in the assay. Other components such as buffers, controls, and the like, known to those of ordinary skill in art, may be included in such test kits. The kits will also include instructions for the use thereof.

[0090] Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.

[0091] Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.

C. Experimental EXAMPLE 1 Identification of a Thioredoxin Reductase from S. aureus

[0092] In order to identify the enzyme responsible for the reduction of oxidized thioredoxin (Trx), S. aureus extracts were analyzed for thioredoxin reductase (TrxB) activity on oxidized thioredoxin in a NADPH-dependent reaction specific for the reduction of insulin as the protein disulfide substrate. 10 ml of an overnight culture of S. aureus RN8325-4 (obtained from Richard Novick at New York University School of Medicine), grown at 37° C. in tryptic soy broth (TSB) medium (Difco Laboratories, Detroit, Mich.), was used to inoculate 0.5 L fresh sterilized TSB medium and the culture was grown for 4 hours. Cells were harvested by centrifugation (8000×g, 15 min), resuspended in 50 mM Tris HCl buffer (20 ml) containing 1 mM EDTA and disrupted by sonication. The homogenized suspension was cleared from insoluble cellular debris by centrifugation and saved. The supernatant was brought to a final concentration of 1% streptomycin sulfate, stirred for 30 min and the nucleic acid precipitate removed by centrifugation. Ammonium sulfate was added to the clear liquid and the fraction that precipitated between 40-80% ammonium sulfate saturation was collected by centrifugation, dissolved in a minimal volume of buffer and chromatographed on a AcA44 gel-filtration size column.

[0093] Fractions exhibiting TrxB activity were separated from those containing the Trx activity and served as the high and low molecular weight protein components, respectively, in the thioredoxin assay. High molecular weight protein fractions were added to a reaction mixture containing an excess of Trx, NADPH and insulin, and the formation of free sulfhydryl (SH) groups in insulin was detected by titration with 5,5′-dithio-bis-2-nitrobenzoic acid (DTNB), which forms a yellow product (TNB, absorbance maximum at 412 nm) on interaction with free thiols. The reduction of the insulin disulfides is strictly dependent on the presence of each of reaction components (NADPH, TrxB, Trx). DTNB may be used in place of insulin as the substrate for the Trx-driven reaction, but is less specific. See, e.g., Ellman (1959) Arch. Biochem. Biophys. 82:70-77.

[0094] A typical assay (Table 1) consisted of a 40 μl fraction of the high molecular weight component from the AcA44 gel-filtration column to which was added 40 μl of a solution containing HEPES buffer pH 7.6, 0.26 M; EDTA 0.01 M; NADPH 2.0 mM; insulin, 1.03 mM. The reaction was initiated by adding a 20 μl fraction of the low molecular weight Trx component eluted from the same gel-filtration column and the mixture was incubated for 20 min at 37° C. The reaction was stopped with 500 μl of a solution containing 0.4 mg DTNB/ml and 6 M Guanidine HCl in 0.2 M Tris HCl, pH 8.0, and the absorbance A₄₁₂ read. Table 1 shows the ability of the S. aureus thioredoxin system to reduce insulin disulfides in the presence of NADPH. TABLE 1 Identification of thioredoxin reductase activity in Staphylococcus aureus Reaction/ Components NADPH Trx^(a) TrxB Insulin A₄₁₂ Trx + − + + 0.493 NADPH − + + + 0.150 Complete + + + + 0.816

[0095] Identification of thioredoxin reductase activity in Staphylococcus aureus

EXAMPLE 2 Purification and Characterization of a Thioredoxin Reductase from S. aureus

[0096] TrxB was purified from cell extracts of S. aureus by following the NADPH-dependent reduction of DTNB. An overnight culture of S. aureus strain RN8325-4 grown in TSB (100 ml) at 37° C. was used as inoculum (5%) for each of two 2L flasks containing TSB (0.5L). Cells were shaken (200 rpm) for 4 hrs at 37° C. before being harvested by centrifugation (Sorvall GSA rotor, 5000 rpm, 15 min). All subsequent handling of the sample prior to chromatography was carried out at 4° C. The cell pellet was resuspended in a minimum of TE buffer (50 mM Tris HCl, pH 8.0, 1 mM EDTA) containing phenylmethylsulphonyl fluoride (PMSF) (1 mM) and lysostaphin (0.5 mg), incubated at 4° C., stirred for 30 min, disrupted further by sonication and then centrifuged (15,000×g, 20 min) to remove insoluble cellular debris. Streptomycin was added to a final concentration of 1%, stirred for 30 min at 4° C. and the nucleic acid precipitate removed by centrifugation. The clear supernatant was brought to 40% saturation with ammonium sulfate, stirred to 15 min, and centrifuged (15,000×g, 10 min). The resulting supernatant was adjusted to 80% saturation with ammonium sulfate and the precipitate collected by centrifugation. The fraction precipitating between 40-80% ammonium sulfate saturation was dissolved in a small volume of buffer and applied to an AcA44 gel-filtration column for size separation chromatography.

[0097] Fractions containing the TrxB activity were easily separated from those containing the Trx activity. Fractions exhibiting TrxB and Trx activity were pooled, dialyzed and applied to a DEAE-Sepharose ion exchange column. The column was washed with the loading buffer (TE) and eluted with a linear gradient of NaCl (0.0-0.5 M) in TE buffer. Fractions containing the TrxB activity were collected and used for further reactions. The purity of fractions showing TrxB activity was determined by SDS-PAGE. The molecular weight of the monomer was determined to be approximately 35 kDa using SDS-PAGE.

EXAMPLE 3 Cloning of the Gene Encoding S. aureus TrxB

[0098] The gene encoding S. aureus TrxB (trxB_(—) Sa) was isolated and sequenced as described below. Generally, the gene was identified by PCR using degenerate primers, shown in Table 2A, based on the conserved N-terminal and C-terminal sequences, shown in Table 2B, of known bacterial thioredoxin reductases. See, e.g., Russell et al. (1988) J. Biol. Chem. 263:9015-9019, for the sequence of E. coli TrxB; Cohen et al. (1993) J. Bacteriol. 175:5159-5167, for the sequence of S. clavuligerus TrxB; Cohen et al. (1994) J. Bacteriol. 176:973-984, for the sequence of Penicillium chrysogenum TrxB; Dai et al. (1996) J. Mol. Biol. 264:1044-1057, for the sequence of Arabidopsis thaliana TrxB; Lubbers et al. (1993) Eur. J. Biochem. 217:791-798, for the sequence of Eubacterium acidominophilum TrxB; and Chae et al. (1994) J. Biol. Chem. 269:27670-27678, for the sequence of Saccharomyces cerevisiae TrxB. The DNA fragment generated by PCR was labeled and used as a probe in the isolation of a 2.8 kB XbaI fragment from S. aureus genomic DNA that carried the trxB gene. The sequence of the open reading frame and the deduced amino acid sequence are shown in FIG. 1 (SEQ ID NO:1) and FIG. 2 (SEQ ID NO:2), respectively. TABLE 2A Degenerate Oligodeoxynucleotide Primers Used in the PCR Amplification of an Internal Region of the Gene Encoding TrxB Oligomer Sequence^(a) P1 5′-ACIACIGAIGTIGA(AG)AA(CT)TT(CT)CC(AGCT)GG-3′ (N-terminal region) (SEQ ID NO: 3) M6 5′-ACGTCICCIGCIGC(AG)AA(AGCT)AC(AGCT)CC-3′ (C-terminal region) (SEQ ID NO: 4)

[0099] TABLE 2B Peptide Regions Specified by Degenerate Oligo- nucleotide Primers Used in PCR Amplification of an Internal Segment of the Gene Encoding TrxB Region Sequence N-terminal peptide TEEVENFPG (SEQ ID NO: 5) C-terminal peptide GIFAAGD (SEQ ID NO: 6)

A. Isolation of a Large Internal DNA Fragment of the trxB Gene

[0100] Degenerate oligodeoxynucleotides which were designed to encode the N-terminal and C-terminal trxB sequences were used as primers for PCR of S. aureus genomic DNA. The PCR reaction contained the following: 100 ng genomic DNA, 50 μm each of 5′-ACIACIGAIGTIGA(AG)AA(CT)TT(CT)CC(AGCT)GG-3′ (SEQ ID NO: 3) and 5′-ACGTCICCIGCIGC(AG)AA(AGCT)AC(AGCT)CC-3′

[0101] (SEQ ID NO:4); MgCl₂ (1.5 mM); bovine serum albumin (BSA) (5 μg); deoxynucleotide triphosphates (dNTPs) (0.2 mM each); and 1×PCR buffer (Fermentas, MBI). The reaction mixture was incubated at 94° C. (1 min), 55° C. (2 min) and 72° C. (2 min) for 30 cycles. The resulting 700 bp PCR product was cloned directly using an AT cloning kit (Promega) and sequenced using universal “forward” and “reverse” primers which are homologous to the flanking region of the multiple cloning site within the plasmid pGEMT (the AT cloning vector (Promega)). The cloning vector including the 700 bp PCR product was termed pOI1.

B. Cloning and Sequencing of the Gene Encoding TrxB

[0102] The fragment from above was labeled with digoxygenin and used to probe Southern blots of S. aureus genomic DNA digested with various restriction enzymes. A single 2.8 kb XbaI fragment that hybridized to the probe under stringent conditions (50% formamide, 42 C) was subcloned into plasmid pUC18 to form pOI2 and sequenced. Initial sequencing primers were designed to prime within the sequence of the PCR fragment described above and to sequence into the flanking regions. New primers were designed within the new sequences and the nucleotide sequence of the entire gene was thus determined stepwise. All of the sequences were confirmed by sequencing both the coding and non-coding strands.

C. Sequence Analysis of S. aureus trxB

[0103] The sequence of the S. aureus trxB gene and the deduced amino acid sequence are shown in FIG. 1 (SEQ ID NO:1) and FIG. 2 (SEQ ID NO:2), respectively. Using the CLUSTALW Program (Thompson et al. (1994) Nucl. Acid Res. 22:4673-4680), the S. aureus TrxB amino acid sequence was compared to other bacterial TrxBs. All parameters used were the standard default parameters recommended by CLUSTALW (see, web site http://www2.ebi.ac.uk/clustalw). Sequence identities found were Bacillus subtilis (72%), Listeria monocytogenes (65%), Clostridium litorale (53%), Mycobacterium leprae (45.5%), Streptomyces coelicolor (43.7%), Escherichia coli (41.9%), Mycoplasma genitalis (35%).

D. Heterologous Overexpression of S. aureus trxB in E. coli

[0104] The open reading frame encoding S. aureus TrxB is amplified by the PCR reaction using the N-terminal primer 5′-GGGAATTCCATATGACTGAAATAGATTTTGAT-3′ (SEQ ID NO:7) and the C-terminal PCR primer 5′-CCCAAGCTTTTAAGCTTGATCGTTTAA-3′ (SEQ ID NO:8). The resulting fragment is digested with NdeI and HindIII, purified and ligated with vector pET14b (Novagen, Inc. Madison Wis.) that is digested with the same two enzymes and purified similarly to produce plasmid pTRSA. An overnight culture (10 mL) of E. coli BL21 (DE3) cells harboring pTRSA is washed twice in 10 ml of TB medium and used as an inoculum for 1 liter of the same medium containing ampicillin (400 mg/mL). The resulting culture is incubated at 37° C. until it reaches mid-stationary phase (A₆₀₀≈1.2), induced to express recombinant TrxB (rTrxB) by the addition of IPTG (to 1 mM) and then incubated for an additional 3 hours at 37° C. The cells are harvested and the recombinant enzyme is purified as described in Example 2 for native TrxB, except that lysozyme (2 mg/mL) is used in place of lysostaphin to assist in disrupting the cells. The purity of the resulting recombinant enzyme is measured by SDS-PAGE and staining with Coomasie brilliant blue.

E. Construction of Gene Replacement Shuttle Vector

[0105] Plasmid pAUL-A (Chakraborty et al. (1992) J. Bacteriol. 174:568-574; FIG. 3), used for trxB inactivation in S. aureus and S. epidermidis, contains a temperature sensitive origin of replication for Staphylococcus such that, when the temperature is raised to 42° C., the plasmid cannot replicate. Additionally, the plasmid contains the origin of replication of pBR322 and is therefore able to propagate in both E. coli and in the above bacteria. If the inactivation plasmid carries a segment of the host chromosome, recombination between the homologous segments will result in the integration of the plasmid. At 42° C., the integrated plasmid can be stably maintained employing selection for the genetic marker, erythromycin resistance, carried on the plasmid sequence. If the homologous chromosomal fragment represents a segment internal to a gene, a single recombinational crossover of the plasmid into the chromosome will cause disruption of the gene and result in the inactivation of the corresponding polypeptide. If the homologous chromosomal fragment contains a deletion internal to a gene, a single recombinational crossover of the plasmid into the chromosome generates a tandem arrangement of wild-type and mutant genes separated by the plasmid sequence; a second recombination event results in loss of one of the copies and the intervening plasmid sequence which, if of the wild-type copy, leads to gene replacement and inactivation of the corresponding polypeptide.

F. Disruption of Chromosomal S. aureus trxB Gene

[0106] The disruption plasmid, pOI7 (FIG. 4), was made as follows. The PCR 700 bp internal trxB fragment was excised from plasmid pOI1 by digestion with BamHI and EcoI within the multiple cloning site, and inserted into pAUL-A to form pOI7. S. aureus strain RN4220 was transformed with pOI7 by electroporation, as described by Schenk, S. and Laddaga, A. (1992) Microbiol. Lett. 94:133-138, and transformants grown at 30° C. or 42° C. (the non-permissive temperature) on plates containing erythromycin. Transformants containing a mutant trxB gene due to disruption of the chromosomal gene were selected for directly at 42° C. From some 2000 transformants tested in this way, four grew up at 42° C. but only one could be further propagated at this temperature. PCR analysis revealed that in this case, and in other cases like it, no evidence was found for stable integration of the disruption vector at the chromosomal trxB locus. This supports the view that disruption of trxB is a lethal event. Control experiments using the pAUL-A plasmid containing a 800 bp internal segment of the S. aureus glnA gene, showed that stable integrants of the plasmid readily occurred at the glnA chromosomal locus.

G. Replacement of Chromosomal S. aureus trxB Gene

[0107] The replacement plasmid was made as follows (see FIGS. 5A and 5B). The 3.1 kb PvuII-HindII tetM (tetracycline resistance) cassette of pRN6680 (Nesin, et al. (1990) Antimicro. Agents. Chemother. 34:2273-2276) was blunt end ligated to the NruVI/Eco721 large fragment of plasmid pOI2 to form pOI4 (FIG. 5A). Plasmid pOI2 is pUC18 containing the 2.8 kB trxB XbaI DNA fragment, as described above. Plasmid pOI4 lacks a large internal segment of the trxB gene. The 5.2 kB Asp718-SalI fragment of pOI4 was inserted into pAUL-A and the resulting plasmid, pOI5 (FIG. 5B) was used to transform by electroporation S. aureus RN4220. Transformants were grown at 42° C. in the presence of erythromycin and tetracycline. The DNAs of six randomly chosen transformants were analyzed by PCR and it was found in each case that the plasmid had integrated into the chromosome by a single crossover event in the DNA flanking region upstream of the trxB gene.

[0108] Phage ØI1 transduction was performed to generate the desired gene replacement, as described by Novick, R. P. Meth. Enzymology 204:587-636. The phage was grown on one of the above integrants at 42° C. in the presence of tetracycline and erythromycin and the lysate used to transduce S. aureus RN4220. Transductants, in which the wild-type copy of trxB had been replaced with the mutant copy due to a phage mediated double crossover recombination event, were screened for at 42° C. on plates containing tetracycline but lacking erythromycin. None of the 750 transductants scored in this way were found to have lost the plasmid erythromycin marker. PCR analysis showed that the transductants contained both the intact and wild-type trxB copies. Alternatively, one of the above integrant strains was propagated for 100 generations (in the presence of tetracycline and absence of erythromycin) to enable spontaneous elimination of either the wild-type or mutant trxB copies. None of the 750 clones tested were found to have lost the erythromycin marker. These results indicate that loss of the wild-type trxB gene is a lethal event and are consistent with the gene disruption experiments described above.

EXAMPLE 4 Identification of Genes Encoding Thioredoxin Reductase in Staphylococcus epidermidis

[0109] The polypeptide sequence of TrxB from S. aureus shown in FIG. 2 (and designated hereinafter of TrxB_(—) Sa) was used to search for genes having similar sequences (and thus theoretically the same functional activity as S. aureus TrxB) in a variety of microorganisms. The database search tool BLAST (Altschul, et al. (1990) J. Mol. Biol. 215:403-410) was employed to search the PathoSeq™ database, version 3.0 (Incyte Pharmaceuticals, Palo Alto, Calif.). Matches were found in the genomic sequence of Staphylococcus epidermidis O-47 (available from Incyte) in the contiguous sequence (contig) designated SEP1c0392. The open reading frame encoding the entire TrxB in the contig was identified and the corresponding polypeptide product deduced. The gene for TrxB in S. epidermidis (designated trxB_(—) Se) is shown in FIG. 6 (SEQ ID NO:9). TrxB_(—) Sa and TrxB_(—) Se were compared by aligning the full-length amino acid sequences using the GAP program. This program considers all possible alignments and gap positions and creates the alignment with the largest number of matched bases and the fewest gaps. A gap creation penalty and gap extension penalty is provided in units of matched bases. The program then creates a gap creation penalty number of matches for each gap it inserts. If a gap extension penalty greater than zero is used, the program also tracks, for each gap inserted, the length of the gap times the gap extension penalty. The GAP program uses the alignment method of Needleman and Wunsch (1970) J. Mol. Biol. 48:443-453.

[0110] The alignment of TrxB_(—) Se and TrxB_(—) Sa is shown in FIG. 7. The sequences show about 90.4% identity and about 93.6% similarity (e.g., conservative amino acid substitutions). The gap weight was 12, length weight 4, quality 1470, ratio 4.727, average match 2.912, average mismatch −2.003, and gaps 0.

EXAMPLE 5 Cloning of the S. epidermidis trxB Gene and Overexpression in E. coli

[0111] The open reading frame encoding the polypeptide TrxB_(—) Se is amplified by PCR from genomic DNA of S. epidermidis O-47 using the N-terminal primer 5′-GGGAATTCCATATGACTGAAGTAGATTTTGAT-3′ (SEQ ID NO:7) and the C-terminal reverse primer 5′-CCCAAGCTTTTAATTATCTTTTAATTCTGT-3′ (SEQ ID NO:8). The resulting amplified fragment is digested with the enzymes NdeII and HindIII and ligated with the vector pET22B(+) (Novagen, Madison Wis.) digested with the same enzymes. The resulting plasmid, designated pTRSE, in introduced in E. coli BL21 (DE3) essentially as in Example 3D. The E. coli strain carrying pTRSE is grown and the TrxB_(—) Se enzyme is isolated essentially as described in Example 3D and analyzed as in Example 1.

EXAMPLE 6 Inactivation of trxB Se

[0112] A 750 bp segment internal to trxB_(—) Se, corresponding to nt 11471-12221, lacking N-terminal and C-terminal sequences coding for essential trxB nucleotide binding domains, is amplified by PCR employing the primers 5′-GGGAATTCGTATATGCATCTCGTGCCAAT-3′ (SEQ ID NO:7) which contains an EcoRI site near the 5′ end and 5′-CCCAATTGTACCTCGTACTTTAGTACTCA-3′ (SEQ ID NO:8) which contains a HindIII site near the 5′ end. The amplified fragment is digested with the enzymes EcoRI and HindIII, and ligated into the vector pAUL-A which is digested with the same enzymes. The resulting plasmid, designated pTRSE-int, is introduced into E. coli. The E. coli strain carrying pTRSE-int is grown and harvested and the plasmid pTRSE-int isolated. The plasmid is electroporated into S. epidermidis following the procedures described in Augustin, J. and Goetz, F. (1990) FEMS Microbiol. Lett. 68:203-208, employing selection for erythromycin resistance. A culture of S. epidermidis/pTRSE-int is grown to mid-log phase in the presence of erythromycin then placed on TSA plates containing erythromycin. To verify that trxB_(—) Se is an essential gene for growth, the plates are incubated at 42° C. and the surviving colonies analyzed for integration of the pTRSE-int plasmid at the chromosomal trxB locus due to a single recombinational crossover event. Inability to isolate cells containing a disrupted trxB gene indicates that trxB_(—) Se is an essential gene for growth.

EXAMPLE 7 High Throughput Assay to Identify Inhibitors Of a Microbial Thioredoxin Reductase

[0113] An insulin assay (modified from A. Holmgren and M. Bjornstedt, (1995) Methods in Enzymology 252:199-208) is used as a sensitive method to monitor the redox-activity of thioredoxin (T) in enabling the NADPH-dependent reduction of insulin disulfides in the presence of thioredoxin reductase (TrxB). In this reaction, TrxB specifically reduces T-S₂ to T-(SH)₂ using NADPH [reaction (1)]. The formed T-(SH)₂ is a powerful reductant of native insulin [reaction (2)].

[0114] The amount of reduced insulin is determined spectrophotometrically at 412 nm after denaturation with 6M guanidine-HCl in the presence of DTNB step 1 in scheme. The reduction of insulin in a reaction that is T-dependent and TrxB-independent is tested spectrophotometrically at 650 nm as an increase in turbidity due to the precipitation of the free (reduced) insulin chain B, step 2 in scheme.

[0115] A. Step I:

[0116] One hundred μl of a reaction mixture containing 0.3 mM insulin, 100 mM HEPES pH 7.5, 3 mM EDTA, 0.5 NADPH, and 1-20 μg of S. aureus TrxB is added to the wells of a series of 96 well microtiter plates. Thioredoxin is omitted from well 1. Wells 3 through 94 contain one of the following: a few μg of the test compound singly, either as a dry powder or in 1-5 μl of 50 mM Tris-HCl, pH 7.8, 50 mM NaCl buffer; a few μg each of a mixture of the test compounds either as a dry powder or in a few μl of 50 mM Tris-HCl, pH 7.8, 50 mM NaCl buffer, for uncharacterized mixtures of compounds derived from bacteria, fungi, plants, marine organisms and present in a few μl of water, buffer, or DMSO. In the first two cases, the amount of compound employed is adjusted so that after all the additions are made the concentration of each compound is in the range of 1-10 μM. Wells 95 and 96 do not contain any compound. To well 1 and to wells 3-96 is added 10 μl of S. aureus TrxB solution containing approximately 300 pmoles in order to start the reaction. Water is added before the addition of TrxB to adjust the volume of each well to 150 μl. The plate is incubated at 37° C. for 20 min. The reaction is terminated by the addition of 150 μl of 0.4 mg/ml DTNB/6 M guanidine hydrochloride in 0.2 M Tris-HCl, pH 8.0 and the absorbance at 412 nm is measured. All compounds that show inhibition of the DTNB reaction are further tested in step II.

[0117] B. Step II:

[0118] (Modified) from A. Holmgren (I 979) J. Biol. Chem. 254:9627-9632)

[0119] Two hundred and fifty μl of the assay mixture containing a freshly prepared solution of bovine insulin, 1 mg/ml of 0.1 M potassium phosphate pH 7.0, 2 mM EDTA, is added to all the wells of a series of 96 well microtiter plates. Thioredoxin solution, 10 μl, is added to wells 3-96 to reach 3-8 μM concentration. Wells 3 through 94 also contain one of the following samples that exhibited inhibition of the DTNB reaction in step I: a few μg of single compounds either as a dry powder or in 1-5 μl of 50 mM Tris-HCl, pH 7.8, 50 mM NaCl buffer, a few μg of a mixture of compounds either as a dry powder or in a few μl of 50 mM Tris-HCl, pH 7.8, 50 mM NaCl buffer; uncharacterized mixtures of compounds derived from bacteria, fungi, plants, marine organisms in a few μl of water, buffer, or DMSO. In the first two cases, the amount of compound employed is adjusted so that after all the additions are made, the concentration of each is in the range of 1-10 μM. Wells 95 and 96 do not contain any compound or extract. The reaction is started by the addition of 10 μl dithiothreitol (DTT) to wells 2-95 to reach a final concentration of 0.3-0.5 mM. The plate is thoroughly agitated and placed in a plate reader and the absorbance at 650 nm is determined. The absorbance is read at intervals of 0.5 min for 80 min. In a typical reaction in the control well 2, containing only DTT and insulin, no precipitation is observed until after about 70 min. In the presence of T and DTT, precipitation appears after 10-15 min.

[0120] In order to evaluate whether a compound is a potential TrxB inhibitor, the compound should exhibit the properties depicted in the flow chart shown as FIG. 8.

[0121] Thus, an isolated S. aureus TrxB polypeptide, DNA coding therefor and methods of using the same to identify inhibitors of TrxB, are provided. Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from the spirit and the scope of the invention as defined by the appended claims.

1 10 1 936 DNA Staphylococcus aureus 1 atgactgaaa tagattttga tatagcaatt atcggtgcag gtccagctgg tatgactgct 60 gcagtatacg catcacgtgc taatttaaaa acagttatga ttgaaagagg tattccaggc 120 ggtcaaatgg ctaatacaga agaagtagag aacttccctg gtttcgaaat gattacaggt 180 ccagatttat ctacaaaaat gtttgaacac gctaaaaagt ttggtgcagt ttatcaatat 240 ggagatatta aatctgtaga agataaaggc gaatataaag tgattaactt tggtaacaaa 300 gaattaacag ctaaagcggt cattattgct acaggtgcag aatacaagaa aattggtgtt 360 ccgggtgaac aagaacttgg tggacgcggt gtaagttatt gtgcagtatg tgatggtgca 420 ttctttaaaa ataaacgcct attcgttatc ggtggtggtg actcagcagt agaagaggga 480 acattcttaa ctaaatttgc tgacaaagta acaatcgttc accgtcgtga tgagttacgt 540 gcacaacgta ttttacaaga tagagcattc aaaaatgata aaatagactt tatttggagc 600 catactttga aatcaattaa tgaaaaagac ggcaaagtgg gttctgtgac attaacgtct 660 acaaaagatg gttcagaaga aacacacgag gctgatggtg tattcatcta tattggtatg 720 aaaccattaa cagcaccatt taaagactta ggtattacaa atgatgttgg ttatattgtg 780 acaaaagatg atatgacaac atcagtacca ggtatttttg cagcaggaga tgttcgcgac 840 aaaggtttac gccaaattgt cactgctact ggcgatggta gtattgcagc acaaagtgca 900 gcggaatata ttgaacattt aaacgatcaa gcttaa 936 2 311 PRT Staphylococcus aureus 2 Met Thr Glu Ile Asp Phe Asp Ile Ala Ile Ile Gly Ala Gly Pro Ala 1 5 10 15 Gly Met Thr Ala Ala Val Tyr Ala Ser Arg Ala Asn Leu Lys Thr Val 20 25 30 Met Ile Glu Arg Gly Ile Pro Gly Gly Gln Met Ala Asn Thr Glu Glu 35 40 45 Val Glu Asn Phe Pro Gly Phe Glu Met Ile Thr Gly Pro Asp Leu Ser 50 55 60 Thr Lys Met Phe Glu His Ala Lys Lys Phe Gly Ala Val Tyr Gln Tyr 65 70 75 80 Gly Asp Ile Lys Ser Val Glu Asp Lys Gly Glu Tyr Lys Val Ile Asn 85 90 95 Phe Gly Asn Lys Glu Leu Thr Ala Lys Ala Val Ile Ile Ala Thr Gly 100 105 110 Ala Glu Tyr Lys Lys Ile Gly Val Pro Gly Glu Gln Glu Leu Gly Gly 115 120 125 Arg Gly Val Ser Tyr Cys Ala Val Cys Asp Gly Ala Phe Phe Lys Asn 130 135 140 Lys Arg Leu Phe Val Ile Gly Gly Gly Asp Ser Ala Val Glu Glu Gly 145 150 155 160 Thr Phe Leu Thr Lys Phe Ala Asp Lys Val Thr Ile Val His Arg Arg 165 170 175 Asp Glu Leu Arg Ala Gln Arg Ile Leu Gln Asp Arg Ala Phe Lys Asn 180 185 190 Asp Lys Ile Asp Phe Ile Trp Ser His Thr Leu Lys Ser Ile Asn Glu 195 200 205 Lys Asp Gly Lys Val Gly Ser Val Thr Leu Thr Ser Thr Lys Asp Gly 210 215 220 Ser Glu Glu Thr His Glu Ala Asp Gly Val Phe Ile Tyr Ile Gly Met 225 230 235 240 Lys Pro Leu Thr Ala Pro Phe Lys Asp Leu Gly Ile Thr Asn Asp Val 245 250 255 Gly Tyr Ile Val Thr Lys Asp Asp Met Thr Thr Ser Val Pro Gly Ile 260 265 270 Phe Ala Ala Gly Asp Val Arg Asp Lys Gly Leu Arg Gln Ile Val Thr 275 280 285 Ala Thr Gly Asp Gly Ser Ile Ala Ala Gln Ser Ala Ala Glu Tyr Ile 290 295 300 Glu His Leu Asn Asp Gln Ala 305 310 3 32 DNA Artificial Sequence N-terminal region primer 3 acnacngang tngaagaact ttctccagct gg 32 4 30 DNA Artificial Sequence C-terminal region primer 4 acgtcnccng cngcagaaag ctacagctcc 30 5 9 PRT Artificial Sequence Primer 5 Thr Glu Glu Val Glu Asn Phe Pro Gly 1 5 6 7 PRT Artificial Sequence Primer 6 Gly Ile Phe Ala Ala Gly Asp 1 5 7 32 DNA Artificial Sequence N-terminal primer 7 gggaattcca tatgactgaa atagattttg at 32 8 27 DNA Artificial Sequence C-terminal primer 8 cccaagcttt taagcttgat cgtttaa 27 9 933 DNA Staphylococcus epidermidis 9 atgactgaag tagattttga tgtagcaata atcggtgcag gtcctgccgg tatgacagca 60 gcagtatatg catctcgtgc caatttaaaa actgtcatca ttgaacgcgg tatgccaggc 120 ggtcaaatgg caaacactga agaagtagag aattttccag gatttgagat gatcacaggt 180 cctgacttat ctactaaaat gtttgaacat gctaaaaaat ttggtgcgga ataccaatat 240 ggcgatatta aatctgttga agataaaggc gactataaag ttatcaattt agggaataaa 300 gagataacag cacatgcagt tattatctca actggagcag agtataaaaa gattggcgtt 360 cctggtgaac aagaattagg aggacgtgga gtaagttatt gtgcggtttg tgatggagca 420 ttctttaaaa ataaacgtct tttcgtaatt ggcggcggag attcagcggt agaagaaggt 480 actttcttaa ctaaatttgc agataaagta acgattgttc accgtagaga tgaattacgt 540 gcacaaaaca tcttgcaaga acgtgccttc aaaaatgata aagttgactt tatttggagt 600 catacactta aaacaattaa tgaaaaagat ggtaaagttg gttcagttac acttgaatca 660 actaaagatg gtgctgaaca gacttatgat gccgacggtg tattcattta tattggaatg 720 aaaccactca cagcaccatt taaaaatctt ggtattacaa atgacgcggg atacattgtc 780 acacaagatg acatgagtac taaagtacga ggtatttttg ctgcaggtga cgttcgtgat 840 aaagggttac gtcaaattgt tactgctaca ggagacggta gtattgcggc tcaaagtgca 900 gctgattata ttacagaatt aaaagataat taa 933 10 310 PRT Staphylococcus epidermidis 10 Met Thr Glu Val Asp Phe Asp Val Ala Ile Ile Gly Ala Gly Pro Ala 1 5 10 15 Gly Met Thr Ala Ala Val Tyr Ala Ser Arg Ala Asn Leu Arg Thr Val 20 25 30 Met Ile Glu Arg Gly Met Pro Gly Gly Gln Met Ala Asn Thr Glu Glu 35 40 45 Val Glu Asn Phe Pro Gly Phe Glu Met Ile Thr Gly Pro Asp Leu Ser 50 55 60 Thr Lys Met Phe Glu His Ala Lys Lys Phe Gly Ala Glu Tyr Gln Tyr 65 70 75 80 Gly Asp Ile Lys Ser Val Glu Asp Lys Gly Asp Tyr Lys Val Ile Asn 85 90 95 Leu Gly Asn Lys Glu Ile Thr Ala His Ala Val Ile Ile Ser Thr Gly 100 105 110 Ala Glu Tyr Lys Lys Ile Gly Val Pro Gly Glu Gln Glu Leu Gly Gly 115 120 125 Arg Gly Val Ser Tyr Cys Ala Val Cys Asp Gly Ala Phe Phe Lys Asn 130 135 140 Lys Arg Leu Phe Val Ile Gly Gly Gly Asp Ser Ala Val Glu Glu Gly 145 150 155 160 Thr Phe Leu Thr Lys Phe Ala Asp Lys Val Thr Ile Val His Arg Arg 165 170 175 Asp Glu Leu Arg Ala Gln Asn Ile Leu Gln Glu Arg Ala Phe Lys Asn 180 185 190 Asp Lys Val Asp Phe Ile Trp Ser His Thr Leu Lys Thr Ile Asn Glu 195 200 205 Lys Asp Gly Lys Val Gly Ser Val Thr Leu Glu Ser Thr Lys Asp Gly 210 215 220 Ala Glu Gln Thr Tyr Asp Ala Asp Gly Val Phe Ile Tyr Ile Gly Met 225 230 235 240 Lys Pro Leu Thr Ala Pro Phe Lys Asn Leu Gly Ile Thr Asn Asp Ala 245 250 255 Gly Tyr Ile Val Thr Gln Asp Asp Met Ser Thr Lys Val Arg Gly Ile 260 265 270 Phe Ala Ala Gly Asp Val Arg Asp Lys Gly Leu Arg Gln Ile Val Thr 275 280 285 Ala Thr Gly Asp Gly Ser Ile Ala Ala Gln Ser Ala Ala Asp Tyr Ile 290 295 300 Thr Glu Leu Lys Asp Asn 305 310 

We claim:
 1. A method for identifying a compound that modulates Staphylococcus thioredoxin reductase (TrxB) activity, comprising: (a) providing a Staphylococcus TrxB polypeptide comprising an amino acid sequence having Staphylococcus thioredoxin reductase activity capable of catalyzing a specific reduction of thioredoxin with a concomitant oxidation of NADPH to NADP⁺; (b) contacting a test compound with the TrxB polypeptide in the presence of thioredoxin, NADPH and a disulfide-containing substrate, under conditions that favor reduction of the disulfide-containing substrate; and (c) detecting the presence of free sulfhydryl groups formed by the reduction of disulfides of the disulfide-containing substrate, as a measure of TrxB activity, thereby identifying a compound that modulates Staphylococcus TrxB activity.
 2. The method of claim 1, wherein the amino acid sequence comprises residues 6-21, 134-137, 146-161 and 267-277 of SEQ ID NO:2 or SEQ ID NO:10; or residues 6-21, 134-137, 146-161 and 267-277 of SEQ ID NO:2 or SEQ ID NO:10, with conservative amino acid substitutions.
 3. The method of claim 1, wherein the amino acid sequence comprises residues 1-277 of SEQ ID NO:2 or SEQ ID NO:10; or residues 1-277 of SEQ ID NO:2 or SEQ ID NO:10, with conservative amino acid substitutions.
 4. The method of claim 1, wherein the amino acid sequence is SEQ ID NO:2, SEQ. ID NO:10, or an amino acid sequence having 90% identity to SEQ ID NO:2 or SEQ ID NO:10.
 5. The method of claim 2, wherein the amino acid sequence comprises SEQ ID NO:2.
 6. The method of claim 2, wherein the amino acid sequence comprises SEQ ID NO:10.
 7. The method of claim 1, wherein the disulfide-containing substrate is insulin.
 8. The method of claim 1, wherein the disulfide-containing substrate is 5,5′-dithio-bis-2-nitrobenzoic acid.
 9. A compound identified by the method of claim 1, wherein the compound modulates Staphylococcus thioredoxin reductase (TrxB) activity.
 10. A composition comprising the compound of claim 9 and a pharmaceutically acceptable excipient.
 11. A method of treating a Staphylococcus infection in an infected subject, comprising administering to the subject an effective antibacterial amount of the composition of claim
 10. 12. The method of claim 11, wherein the infection comprises a Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus albus, Staphylococcus hyicus, Staphylococcus hyos, Staphylococcus intermedius or Staphylococcus simulans infection.
 13. The method of claim 12, wherein the infection is a Staphylococcus aureus infection. 